Timing matters: study looks at when to start MS drug kesimpta
NCT ID NCT05776888
First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 19 times
Summary
This study follows 106 people with relapsing multiple sclerosis in Austria to see if starting the drug Ofatumumab (Kesimpta) earlier makes a difference compared to starting it later. Over two years, researchers track how well the drug controls disease activity, including relapses and brain scan changes. The goal is to understand the real-world benefits of early treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.